Zürich, Switzerland, May 2025 – Beata Czajkowska has stepped into a new leadership role as Senior Director, Talent Access International at Madrigal Pharmaceuticals, a biopharmaceutical company focused on developing novel therapies for MASH (Metabolic Dysfunction-Associated Steatohepatitis), a serious liver disease with significant unmet medical need. In her new role, Beata will lead international talent strategy to support the organization’s continued global growth and mission of transforming patient outcomes.
Beata brings with her over a decade of experience in global talent acquisition across Europe, the Middle East, Africa, and Asia. Prior to joining Madrigal Pharmaceuticals, she served as Director, Talent Acquisition, Global Operations & EMEA at CSL, where she was responsible for leading talent acquisition across international markets while supporting the company’s expansion in the biopharma space.
Before CSL, Beata had a distinguished 8-year tenure at Alexion Pharmaceuticals (now part of AstraZeneca), holding progressively senior positions including Director, Talent Acquisition Lead, International & Japan and Associate Director, Talent Acquisition Lead EMEAC. During this time, she led major recruitment initiatives across rare diseases and helped align global talent efforts with Alexion’s strategic therapeutic priorities.
Earlier in her career, Beata worked at Amgen in various regional roles, including Senior Associate, Talent Acquisition Operations and Interim Talent Acquisition Manager for the Netherlands. She also held talent acquisition roles at Newell Brands, where she oversaw pan-EMEA hiring, and began her HR journey in marketing roles at HolidayCheck AG and Portal Project Management International.
Her extensive experience across large multinational pharmaceutical and consumer product organizations has equipped her with deep insights into international recruitment, workforce planning, and employer branding.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), also known as MASH. The company’s first therapeutic received accelerated FDA approval for treating NASH with moderate to advanced liver fibrosis. Madrigal continues to lead the way in hepatology with several ongoing clinical studies and is committed to improving lives through scientific breakthroughs and transformative care.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
